Results 1 to 10 of about 5,090 (179)

Activity of TNT: a phase 2 study using talimogene laherparepvec, nivolumab and trabectedin for previously treated patients with advanced sarcomas (NCT# 03886311) [PDF]

Frontiers in Oncology, 2023
BackgroundIntratumoral injection of talimogene laherparepvec evokes a cytotoxic immune response. Therefore, the combination of talimogene laherparepvec with trabectedin and nivolumab may have synergistic effects in advanced sarcomas.Patients and ...
Sant P. Chawla, Walter Andree Tellez, Hripsime Chomoyan, Chrysler Valencia, Amir Ahari, Nadezhda Omelchenko, Stefan Makrievski, Don A. Brigham, Don A. Brigham, Victoria Chua-Alcala, Doris Quon, Ania Moradkhani, Erlinda M. Gordon, Erlinda M. Gordon   +13 more
doaj   +4 more sources

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma [PDF]

Journal for ImmunoTherapy of Cancer, 2019
Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB–IVM1c
Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman   +6 more
doaj   +5 more sources

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection [PDF]

JAAD Case Reports, 2022
Leonid Shmuylovich, MD, PhD, Aubriana M. McEvoy, MD, MS, Ryan C. Fields, MD, Leonel Hernandez-Aya, MD, George Ansstas, MD, David Y. Chen, MD, PhD   +5 more
doaj   +5 more sources

Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial [PDF]

Molecular Therapy: Oncology
Peritoneal surface malignancies (PSMs) remain a therapeutic challenge, particularly in patients with unresectable disease who cannot benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
John H. Stewart, IV, Donna Niedzwiecki, Melissa Lowe, Ashley Moyer, Emily Bolch, Shannon Diane MacLaughlan, Edward A. Levine, Omeed Moaven, Niharika Mettu, John H. Strickler, Dan G. Blazer, III   +10 more
doaj   +2 more sources

Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class [PDF]

Frontiers in Molecular Biosciences, 2022
Talimogene laherparepvec (T-VEC) is a modified oncolytic herpes Simplex virus, type 1 (HSV-1) encoding granulocyte-macrophage colony stimulating factor (GM-CSF).
Howard L. Kaufman, Howard L. Kaufman, Sophia Z. Shalhout, Gail Iodice   +3 more
doaj   +2 more sources

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report [PDF]

Journal of Medical Case Reports
Background Mucosal melanoma, an aggressive type of malignancy different from the cutaneous melanomas commonly seen in the head and neck region, represents 
Saurabh D. Chitnis, Nolan B. Seim, Kari Kendra   +2 more
doaj   +2 more sources

A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma [PDF]

Clinical Case Reports
Cytomegalovirus (CMV) reactivation is a rare complication in patients treated with immune checkpoint inhibitors (ICIs), typically occurring after immunosuppressive therapy for immune‐related adverse events (irAEs). Here, we report a unique case of severe
Goar Egoryan, Alex Zimmet, Mingwei Yu, Joseph Pozdol, Aruna Subramanian, Sunil Reddy, Joanna Nelson   +6 more
doaj   +2 more sources

Tumoral melanosis mimicking residual melanoma in the setting of talimogene laherparepvec treatment [PDF]

Journal for ImmunoTherapy of Cancer, 2022
Talimogene laherparepvec (T-VEC) has become an increasingly popular treatment option for surgically non-resectable, recurrent melanoma, usually of cutaneous metastases.
Jennifer Gardner, Song Y Park, Austin R Green, Rouba Hadi, Coley Doolittle-Amieva, Ata S Moshiri   +5 more
doaj   +2 more sources

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. [PDF]

Front Pediatr, 2023
BACKGROUND The survival rates for pediatric patients with relapsed and refractory tumors are poor. Successful treatment strategies are currently lacking and there remains an unmet need for novel therapies for these patients. We report here the results
Moreno L, Teira P, Croop JM, Gerber NU, André N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA.   +13 more
europepmc   +6 more sources

Talimogene Laherparepvec treatment for mucosal melanoma with metastatic lymph node metastasis: case report [PDF]

Frontiers in Oncology
Mucosal melanoma is a rare and aggressive subtype of melanoma, accounting for approximately 1% of all melanoma cases. Of those, only 4% occur primarily in the vagina.
Arnar B. Ingason, Venkatesa P. Muruganandam, Ikechukwu Chidobem, Jessica Cintolo-Gonzalez, Hibba tul Rehman   +4 more
doaj   +2 more sources